Parexel and Datavant partner on clinical study design, operations

Doctor computer medical records
The partnership is designed to connect healthcare data from a number of real-world and clinical data sources to spur improved drug development and commercialization, the companies said. (Getty/BrianAJackson)

Parexel and Datavant, which focuses on healthcare technology, are partnering to improve the design and operations of clinical studies and the generation of real-world evidence.

The partnership is designed to connect healthcare data from a number of real-world and clinical data sources to spur improved drug development and commercialization, the companies said.

Datavant targets secure de-identification and linking of healthcare datasets.

Sponsored by Biotech Primer

September 2-3, 2020 Live, Online Course: Biopharma Revenue Forecasting that Drives Decision Making and Investments

Become fluent in the core elements of revenue forecasting including epidemiology, competitive assessments, market share assignment and pricing. Let Biotech Primer's dynamic industry experts teach you how to assess the value of new therapies.

“The exponential growth of healthcare data offers both an opportunity to incorporate this wealth of data into the clinical study processes and commercial evidence generation, and a challenge, given the disparate sources where a patient’s healthcare data may be contained,” Jason Martin, Parexel’s VP of Global Data Operations, said in a statement.

San Francisco-based Datavant’s tech allows the linking of traditional healthcare data sources like electronic medical records, claims and diagnostics with other emerging sources such as genomics, socioeconomic data, information from wearable devices and behavioral data.

Travis May, Datavant’s chief executive, said the partnership will provide “an opportunity to answer some of the most difficult questions in drug development and commercialization for the ultimate benefit of patients.”

Suggested Articles

Contract Research Organization PPD has seen its revenue nudge up in the second quarter as it navigates trial disruption.

Biopharma cancer drug developer Cassandra Matney, M.D., has joined CRO Premier Research as its new senior medical director.

As the pandemic rages on and clinical trials are becoming increasingly siteless, eSource trial firm Clinical Ink has become an M&A target.